We are driven by a passionfor transforming products into brands and patients into survivors. Navicor is a 100% healthcare-focused, full-service agency that understands the unique aspects of the oncology marketplace. We have extensive oncology launch experience and have partnerships with large and small pharma and biotech companies.
The Avoca Quality Consortium Summit, held May 8-9, 2013, in
Princeton, NJ, was the Second Annual meeting for The Avoca
Group’s Quality Consortium, a cooperative effort that brings
together quality, outsourcing, and operational professionals
from Member pharma, biotech, and CRO organizations to
accelerate the development of a best-practices approach to
quality management and CRO oversight.
Currently, the Avoca Group’s Quality Consortium includes
26 Members: 16 pharma/biotech companies and 10 Contract
Research Organizations (CROs). The corporate sponsors of the Quality Consortium are Eli Lilly and Company and Pfizer, Inc. ICON Clinical Research was the corporate sponsor of the May Summit.
Special thanks to our Executive Summary Sponsor,
inVentiv Health Clinical.
These slides use concepts from my (Jeff Funk) course on Business Models at National University of Singapore to analyze the business model for Theranos. Theranos provides diagnostic testing for consumers that is faster and cheaper than the existing system. Its tests are done in easy to access pharmacies (e.g., Walgreens) as opposed to hard-to reach doctors’ offices. The tests use small bio-electronic integrated circuits (ICs) instead of large scientific instruments. These ICs utilize micro-fluidic channels that require a pin-prick of blood instead of a vial of blood, which makes the tests more appealing and faster than the traditional tests. The slides describe the value proposition, method of value capture, customers, scope of activities, and method of strategic control for Theranos.
Making Life Easier for Investigators: A Shared Solution for Smarter, Faster C...Cognizant
The industry's Shared Investigator Platform significantly reduces the time and cost of clinical trials, simplifying work for investigators and bringing promising therapies to market more quickly.
Clinical evaluation and the latest 2016 guidelineGRCTS
This “General Guidance” document promotes a common approach to clinical evaluation for "medical devices regulated by directives 90/385/EEC and 93/42/EEC. It does not concern in vitro diagnostic devices. The depth and extent of clinical evaluations should be flexible and appropriate to the nature, intended purpose, and risks of the device in question.
This Slideshare discusses the current state, technical and workflow challenges, and the future state of Patient Generated Health Data. Learn more: https://accntu.re/2KeGkZ6
The State of Clinical Outsourcing: Managing Risk in Outsourced Clinical Trials
Interactive Discussion Based on Data from Avoca’s 2013 Industry Research DIA Forum
June 24, 2013
We are driven by a passionfor transforming products into brands and patients into survivors. Navicor is a 100% healthcare-focused, full-service agency that understands the unique aspects of the oncology marketplace. We have extensive oncology launch experience and have partnerships with large and small pharma and biotech companies.
The Avoca Quality Consortium Summit, held May 8-9, 2013, in
Princeton, NJ, was the Second Annual meeting for The Avoca
Group’s Quality Consortium, a cooperative effort that brings
together quality, outsourcing, and operational professionals
from Member pharma, biotech, and CRO organizations to
accelerate the development of a best-practices approach to
quality management and CRO oversight.
Currently, the Avoca Group’s Quality Consortium includes
26 Members: 16 pharma/biotech companies and 10 Contract
Research Organizations (CROs). The corporate sponsors of the Quality Consortium are Eli Lilly and Company and Pfizer, Inc. ICON Clinical Research was the corporate sponsor of the May Summit.
Special thanks to our Executive Summary Sponsor,
inVentiv Health Clinical.
These slides use concepts from my (Jeff Funk) course on Business Models at National University of Singapore to analyze the business model for Theranos. Theranos provides diagnostic testing for consumers that is faster and cheaper than the existing system. Its tests are done in easy to access pharmacies (e.g., Walgreens) as opposed to hard-to reach doctors’ offices. The tests use small bio-electronic integrated circuits (ICs) instead of large scientific instruments. These ICs utilize micro-fluidic channels that require a pin-prick of blood instead of a vial of blood, which makes the tests more appealing and faster than the traditional tests. The slides describe the value proposition, method of value capture, customers, scope of activities, and method of strategic control for Theranos.
Making Life Easier for Investigators: A Shared Solution for Smarter, Faster C...Cognizant
The industry's Shared Investigator Platform significantly reduces the time and cost of clinical trials, simplifying work for investigators and bringing promising therapies to market more quickly.
Clinical evaluation and the latest 2016 guidelineGRCTS
This “General Guidance” document promotes a common approach to clinical evaluation for "medical devices regulated by directives 90/385/EEC and 93/42/EEC. It does not concern in vitro diagnostic devices. The depth and extent of clinical evaluations should be flexible and appropriate to the nature, intended purpose, and risks of the device in question.
This Slideshare discusses the current state, technical and workflow challenges, and the future state of Patient Generated Health Data. Learn more: https://accntu.re/2KeGkZ6
The State of Clinical Outsourcing: Managing Risk in Outsourced Clinical Trials
Interactive Discussion Based on Data from Avoca’s 2013 Industry Research DIA Forum
June 24, 2013
J&J: Transforming Study Start-up in a Global Environment Veeva Systems
In this presentation, Lisa Rakebrand, Director Clinical R&D at J&J, discusses her team's vision to transform the way study start-up is conducted globally by leveraging Vault Study Startup to improve site collaboration, streamline site activation, and speed study start-up.
Transforming How Sponsors and CROs Interact with Clinical SitesPerficient, Inc.
Clinical trials are expensive. With the constraints of quality and compliance, the only way to reduce costs is to make trial operations more efficient. When study sponsors are able to automate workflows and efficiently exchange information, documents, queries, and supplies with their clinical sites, good things happen: confusion and errors are minimized, relationships with investigators and site personnel improve, and overhead costs plummet.
In this SlideShare, we discuss how organizations can use strategy, technology, and design to reduce clinical trial costs while improving quality and compliance.
Preliminary results from a survey on the use of metrics and evaluation strate...jehill3
Preliminary results from a survey on the use of metrics and evaluation strategies among mHealth projects
Patricia Mechael, Nadi Kaonga
Center for Global Health and Economic Development at the Earth Institute, Columbia University
CORE Group Spring Meeting, April 30, 2010
Clinical Affairs Excellence: Benchmarking Clinical Trial Strategies To Ensure...Best Practices
In the face of cost and regulatory pressures, clinical programs at medical device organizations have looked to less expensive and regulated areas of the world to perform clinical trial activities. Emerging markets are also fast-growing regions that present future growth opportunities for organizations that have seen sales growth slow in mature markets. However, there are still questions around the cost, acceptability, quality and pitfalls of conducting clinical trials in emerging regions.
Best Practices®, LLC conducted primary research to inform clinical affairs leaders at medical device companies on emerging approaches to staffing, outsourcing and managing clinical trials outside of the European and U.S. regions.
Critical outsourcing questions addressed in this survey include:
-What are the regions where medical device companies are conducting clinical trials and the percent of patients recruited annually from these regions?
-Which clinical trial activities are best suited for outsourcing?
-What is the appropriate staffing mix (in-house and outsourced) for clinical trials?
-What are the most important competencies for clinical research associates, managers, and directors?
This report will inform Clinical Affairs leaders on these questions and others regarding staffing, outsourcing and managing clinical trials outside of the U.S.
“Pharmaceutical Quality Matrices in determining overall state of Quality and ...Marcep Inc.
Introduction to Quality Matrices
•What is Quality metrics
Background&Glossary
•Modernization of Regulatory Oversight of Drug Quality and Promotion of Post-Approval Improvements
•Use of Quality Metrics by FDA for Risk-Based Inspection Scheduling and Prediction of Drug Shortages
Legal authority
•Records Associated with the Process Validation Lifecycle and PQS Assessment
•Authority to Inspect Records and Request in Advance of or In Lieu of an Inspection
The Use of Quality Metrics and Effect of Non-Reporting
•How FDA Intends to Use Quality Metrics
•Effect of Non-Reporting
Group Discussion:
Implementing Trending of Quality Indices in Your Organization
The importance of the right culture and people
• Role of leadership in trending of Quality Indices
• Developing anonline data base for Quality Indices
•Analysis, interpretation and reporting of Quality Indices
The Process Flow
• Establishing the ground rules, procedures, forms and mechanismfor data collection for Quality indices
• Determining responsibilities and roles for the implementation of trending of Quality Indices
Starting the Quality Indices Management Process
•Review of Quality Indices and Gap evaluation
•Preparation of Data bases for Data acquisition
•Collection data for completeness and Accuracy
•Processing and Reporting of Quality Metrics
Day Two
Reporting of Quality data and Calculation of Quality Metrics
• Who Reports and Who May Contribute to the Report
• Quality Metrics that FDA Intends to Calculate
• What Quality Data Would Be Reported
• How to Report Quality Data to FDA
Instructions for Quality Metric Data Submission
•Worksheet for Data Tables
•Product Specific Information
•Mandatory Data •ICH Q9
•Optional Metrics
Recognizing and Understanding the Trending of Quality Indices
Working Session, I:
•Participants will be divided into groups and given acase study and be asked to perform a trend analysis on a given data. Each group will present theresults of its analysis
Working Session II:
•Participants will be divided into groups and given acase study and be asked to perform a trend analysis and propose a Quality metric by using Risk Based approach for the specific set of data. The results of the analyses willbe shared in the class.
Complexities of Implementation Quality Metrics
•Overcoming the pitfalls
•Benefits and Risks
General Discussion and Questions
Tackling the Challanges of Pharma ManufacturingJason Corder
By nature, pharmaceutical manufacturing operations are complex, inefficient, and consequently costly. Due to the inherent complexities, the cost of poor efficiency and its root causes are often not well understood by many manufacturers.
Leverage Big Data Analytics to Enhance Clinical Trials from Planning to Execu...Saama
Nikhil Gopinath, Senior Solutions Engineer for the Life Sciences at Saama, spoke at EyeforPharma's Clinical Trial Innovation Summit event in February 2017. These slides are from his "Leverage Big Data Analytics to Enhance Clinical Trials from Planning to Execution" presentation.
Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. Therefore, it is absolutely critical for bio-pharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.
According to recent research by Best Practices, LLC, nearly three-quarters of the benchmarked study participants use review cycle time as a metric for determining if the market research approval process is functioning at an acceptable level. One tip that participants gave on how to control processes and to ensure high performance is to create checklists. Begin with checklists in pinch points that are most problematic, and then extend to entire process and operations. This report will help leaders to gain critical insights they need to compete successfully in a fast-changing market.
Download Full Report: http://bit.ly/2bfAhOc
Field Interactive MR’s consumer-panel, B2B-Panel, Healthcare-Panel and data collection capabilities in 98 countries helps our clients analyze the market, gain valuable insight and genuinely understand consumers.
For more information, please visit - http://fieldinteractive-mr.com/
PATRICIA LEUCHTEN WINS BRONZE STEVIE® AWARD IN 2013 STEVIE AWARDS FOR WOMEN I...The Avoca Group
Patricia Leuchten, founder and CEO of pharmaceutical consulting and survey research firm The Avoca Group, has been named the winner of a Bronze Stevie® Award in the ‘Maverick of the Year’ category. Leuchten accepted the award at the 10th annual Stevie Awards for Women in Business held in New York City.
Tata Group Dials Taiwan for Its Chipmaking Ambition in Gujarat’s DholeraAvirahi City Dholera
The Tata Group, a titan of Indian industry, is making waves with its advanced talks with Taiwanese chipmakers Powerchip Semiconductor Manufacturing Corporation (PSMC) and UMC Group. The goal? Establishing a cutting-edge semiconductor fabrication unit (fab) in Dholera, Gujarat. This isn’t just any project; it’s a potential game changer for India’s chipmaking aspirations and a boon for investors seeking promising residential projects in dholera sir.
Visit : https://www.avirahi.com/blog/tata-group-dials-taiwan-for-its-chipmaking-ambition-in-gujarats-dholera/
Attending a job Interview for B1 and B2 Englsih learnersErika906060
It is a sample of an interview for a business english class for pre-intermediate and intermediate english students with emphasis on the speking ability.
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
Affordable Stationery Printing Services in Jaipur | Navpack n PrintNavpack & Print
Looking for professional printing services in Jaipur? Navpack n Print offers high-quality and affordable stationery printing for all your business needs. Stand out with custom stationery designs and fast turnaround times. Contact us today for a quote!
Improving profitability for small businessBen Wann
In this comprehensive presentation, we will explore strategies and practical tips for enhancing profitability in small businesses. Tailored to meet the unique challenges faced by small enterprises, this session covers various aspects that directly impact the bottom line. Attendees will learn how to optimize operational efficiency, manage expenses, and increase revenue through innovative marketing and customer engagement techniques.
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
[Note: This is a partial preview. To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
Sustainability has become an increasingly critical topic as the world recognizes the need to protect our planet and its resources for future generations. Sustainability means meeting our current needs without compromising the ability of future generations to meet theirs. It involves long-term planning and consideration of the consequences of our actions. The goal is to create strategies that ensure the long-term viability of People, Planet, and Profit.
Leading companies such as Nike, Toyota, and Siemens are prioritizing sustainable innovation in their business models, setting an example for others to follow. In this Sustainability training presentation, you will learn key concepts, principles, and practices of sustainability applicable across industries. This training aims to create awareness and educate employees, senior executives, consultants, and other key stakeholders, including investors, policymakers, and supply chain partners, on the importance and implementation of sustainability.
LEARNING OBJECTIVES
1. Develop a comprehensive understanding of the fundamental principles and concepts that form the foundation of sustainability within corporate environments.
2. Explore the sustainability implementation model, focusing on effective measures and reporting strategies to track and communicate sustainability efforts.
3. Identify and define best practices and critical success factors essential for achieving sustainability goals within organizations.
CONTENTS
1. Introduction and Key Concepts of Sustainability
2. Principles and Practices of Sustainability
3. Measures and Reporting in Sustainability
4. Sustainability Implementation & Best Practices
To download the complete presentation, visit: https://www.oeconsulting.com.sg/training-presentations
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...BBPMedia1
Marvin neemt je in deze presentatie mee in de voordelen van non-endemic advertising op retail media netwerken. Hij brengt ook de uitdagingen in beeld die de markt op dit moment heeft op het gebied van retail media voor niet-leveranciers.
Retail media wordt gezien als het nieuwe advertising-medium en ook mediabureaus richten massaal retail media-afdelingen op. Merken die niet in de betreffende winkel liggen staan ook nog niet in de rij om op de retail media netwerken te adverteren. Marvin belicht de uitdagingen die er zijn om echt aansluiting te vinden op die markt van non-endemic advertising.
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
Search Disrupted Google’s Leaked Documents Rock the SEO World.pdf
Avoca 2014 DIA Presentation
1. The State of Clinical Outsourcing:
Do Outsourcing Partnerships Promote or Impede
Progress toward Clinical Trial Optimization?
Data from the 2014 Avoca Industry Survey
Denise Calaprice-Whitty, Ph.D.
Senior Consultant
The Avoca Group
@TheAvocaGroup
2. Disclaimer
• The views and opinions expressed in the following PowerPoint
slides are those of the individual presenter and should not be
attributed to Drug Information Association, Inc. (“DIA”), its directors,
officers, employees, volunteers, members, chapters, councils,
Communities or affiliates, or any organization with which the
presenter is employed or affiliated.
• These PowerPoint slides are the intellectual property of the
individual presenter and are protected under the copyright laws of
the United States of America and other countries. Used by
permission. All rights reserved. Drug Information Association, Drug
Information Association Inc., DIA and DIA logo are registered
trademarks. All other trademarks are the property of their respective
owners.
2
3. 3
Panel Members
Denise Calaprice-Whitty, Ph.D. (Moderator)
Senior Consultant, The Avoca Group
Rhonda Henry
Vice President of Alliance Management and Strategic Sales, PPDI
Elspeth Carnan, Ph.D.
Executive Director, Center of Operational Efficiency, Innovation,
and Process Improvement, Global Development Ops, Amgen
Kathleen Ford
Senior Vice President, Head of Global Clinical Operations, Merck
4. 4
2014 Avoca Industry Survey
The Big Question:
How are “intelligent,”
data-driven approaches*
being used in clinical
development today?
What factors promote their use, and
what factors inhibit it (with a focus on
outsourcing)?
5. 5
Survey Definition
* “Intelligent,” data-driven approach:
One that makes use of operational (e.g. performance) and/or clinical
data…
along with appropriate analytical techniques,
in order to optimize aspects of clinical development (protocol design,
Investigator selection, patient recruitment approaches, resource allocation,
e.g. risk-based monitoring), etc.
6. 6
Background: 2014 Avoca Industry Survey
Why now?
• “Big Data” concepts have become part of our daily experience,
with successful and highly visible use in other industries
• In our industry, unprecedented availability and aggregation of
digital information
– Even further promoted by high rates of outsourcing
• Continued time, cost, and quality pressures on clinical
development
• Clear areas of opportunity
7. 7
• Areas of opportunity, examples:
– Overall protocol design
– Procedural or eligibility aspects of protocols
– Selection of sites, regions, providers, or patient
recruitment approaches
– Project management/oversight
As with any change, however, companies must recognize
and effectively manage the forces that impact uptake and
success.
Background: 2014 Avoca Industry Survey
8. 8
Specific research questions addressed:
• Frequency of use of “intelligent” approaches in different key
areas
• Rate of advancement over the last 2 years
• Forces contributing (positively or negatively) to advancement
– General
– Impact of outsourcing partnerships and outsourcing models
• Early engagement of partners in protocol and development planning
• Experience with technology, training, and other implementation
and change management solutions
Background: 2014 Avoca Industry Survey
9. 9
2014 Avoca Industry Survey: Respondents
Sponsors:
127 Respondents
• Approximately 45% in top 20 in terms
of revenue
– 67% Pharma
– 28% Biotech
– 3% Device
– 2% Combination/Other
Clinical Service Providers:
105 Respondents
• 64% in top 20 in terms of revenue
– 67% CROs
– 33% Other/Niche
10. 10
Results: Application of Approaches
How frequently are “intelligent”
approaches applied?
How much advancement has been
made in the last 2 years?
11. 11
% of Respondents Reporting that Most of their Clinical Trials Use
“Intelligent” Approaches
(activities performed by the respondent’s company)
0% 20% 40% 60%
Provider selection
Cost benchmarking/
management
Region selection
Specific protocol procedures
or eligibility criteria
Site selection
Project management/
oversight
Overall protocol designs
Data collection tools
Patient/volunteer
recruitment
Monitoring
(e.g. risk-based)
Sponsors (N=87)
0% 20% 40% 60%
Site selection
Region selection
Project management/
oversight
Cost benchmarking/
management
Data collection tools
Provider selection
Specific protocol procedures
or eligibility criteria
Patient/volunteer
recruitment
Monitoring
(e.g. risk-based)
Overall protocol designs
Providers (N=62)
12. 12
% of Respondents Reporting at least “Moderate Advances” in the Use of
“Intelligent” Approaches over the Last 2 years
(activities performed by the respondent’s company)
0% 20% 40% 60% 80%
Provider selection
Site selection
Project management/
oversight
Overall protocol designs
Specific protocol procedures
or eligibility criteria
Cost benchmarking/
management
Region selection
Data collection tools
Monitoring
Patient/volunteer
recruitment
Sponsors (N=84)
0% 20% 40% 60% 80%
Region selection
Site selection
Data collection tools
Monitoring
Provider selection
Specific protocol procedures
or eligibility criteria
Project management/
oversight
Cost benchmarking/
management
Overall protocol designs
Patient/volunteer
recruitment
Providers (N=65)
13. 13
% of Respondents Reporting “Great Advances” in the Use of
“Intelligent” Approaches over the Last 2 years
(activities performed by the respondent’s company)
0% 10% 20% 30% 40%
Provider selection
Overall protocol designs
Data collection tools
Monitoring
Project management/
oversight
Cost benchmarking/
management
Patient/volunteer
recruitment
Specific protocol procedures
or eligibility criteria
Site selection
Region selection
Sponsors (N=84)
0% 10% 20% 30% 40%
Site selection
Monitoring
Data collection tools
Patient/volunteer
recruitment
Region selection
Overall protocol designs
Provider selection
Project management/
oversight
Specific protocol procedures
or eligibility criteria
Cost benchmarking/
management
Providers (N=65)
14. 14
Results: Impact of Outsourcing on
Application
To what extent does the use of “intelligent”
approaches depend (positively or negatively)
on outsourcing?
Why and in what ways?
15. 15
Sponsors: To what extent do your company's clinical service
providers either contribute to, or detract from, your company's
use of "intelligent” clinical development approaches?
19%
14%
21%
22%
7%
15%
4%
7%
3%
7%
50%
43%
37%
35%
37%
29%
36%
31%
26%
21%
26%
27%
35%
32%
36%
36%
41%
50%
40%
52%
46%
39%
3%
6%
7%
6%
13%
15%
11%
20%
20%
26%
26%
4%
6%
9%
0% 20% 40% 60% 80% 100%
Site selection
Region selection
Monitoring (e.g. risk-based monitoring)
Patient/volunteer recruitment
Project management/oversight
Data collection tools
Other operational processes
Provider selection
Specific protocol procedures or eligibility
criteria
Overall protocol designs (e.g. adaptive)
Cost benchmarking/management
Essential contribution Significant contribution Little contribution
No contribution Negative contribution
N
70
69
73
72
67
68
56
55
66
57
57
16. 16
Provider Contributions
• Availability of data
• Availability of models and experience
• Understanding of regulatory perspective
• Technology
• Resource availability
17. 17
Levels of Satisfaction with the Application of
“Intelligent" Approaches
(rating scale 1=very dissatisfied to 5=very satisfied)
Sponsor ratings
Difference
Service
provider
self ratings
In-house
teams
Service
providers
N= 65 54 54
Cost benchmarking/management 3.3 2.5 0.8 3.2
Provider selection 3.4 2.9 0.5 3.4
Overall protocol designs (e.g.
adaptive)
3.4 2.9 0.5 3.8
Specific protocol procedures or
eligibility criteria
3.4 3.0 0.4 3.7
Project management/oversight 3.4 3.0 0.4 3.4
Site selection 3.3 3.1 0.2 3.9
Region selection 3.4 3.3 0.1 3.7
Patient/volunteer recruitment 3.2 3.1 0.1 3.6
Data collection tools (e.g. designs
associated with lowest query rates)
3.4 3.3 0.1 3.7
Other operational processes 3.2 3.1 0.1 3.4
Monitoring (e.g. risk-based monitoring) 3.1 3.1 0 3.5
18. 18
Sponsors: For outsourced clinical trials, how often do you engage
CROs early in the clinical trial execution process in order to leverage
their experience?
19%
43%
31%
5% 2%
Always
Most of the time
Sometimes
Seldom
Never
N=86
19. 19
Sponsors: Collaboration with CROs on
Protocol Design
7%
16%
29%24%
24%
Always
Most of the time
Sometimes
Seldom
Never
17%
54%
23%
5% 1% Greatly
Somewhat
Little
None
Reduces protocol
quality
For outsourced clinical trials, how
often do you collaborate with your
CROs on protocol design?
To what extent do you feel that
collaboration with CROs on
protocol design improves quality?
N=83 N=76
20. 20
Results: Impact of Outsourcing on
Application
Does the outsourcing model make a difference?
21. 21
Impacts of Full-Service vs. Functional
• Strong opinions in both directions!
• Full-service outsourcing:
– Promotes approaches that require data to be shared, or tasks to be
coordinated, across functional areas (e.g. fully integrated intelligent
technologies)
– Promotes greater sense of ownership among CROs, hence promoting use
of more optimized approaches
– But can impede optimization since much is limited by weakest provider
areas
• Functional outsourcing:
– Promotes excellence and efficiency in single tasks
22. 22
Impacts of Strategic Alliances
• Positive impacts:
– Aggregation of data for partnership studies
– Access to data as part of Agreement
– Greater investment in aligned systems, metrics, processes
– Cost benefits allow more resources to be directed toward innovation
– Dedicated resources: positive impact on resource availability
– Increases trust, hence willingness to innovate
– More cooperation in early stages of programs ◊ opportunity to
discuss and plan
– Partners under increased pressure to show value, so come up with
more creative approaches
23. 23
Impacts of Strategic Alliances
• Negative impacts:
– Lack of competition removes incentive to innovate
• get “comfortable”
– Fewer benefits of cross-vendor expertise
• constrains alliance partners from freely partnering to
leverage unique systems and tools.